BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6211
- TODAY'S CHANGE (%)-0.0079 (-1.2481%)
- Bid / Lots0.6200/ 15
- Ask / Lots0.6570/ 20
- Open / Previous Close0.6300 / 0.6290
- Day Range
- 52 Week Range
- Volume166,547
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 1143 | 0.63 |
| 09:50 ET | 147 | 0.630001 |
| 09:59 ET | 100 | 0.64 |
| 10:01 ET | 1000 | 0.6201 |
| 10:17 ET | 5000 | 0.62 |
| 10:28 ET | 3000 | 0.62025 |
| 10:32 ET | 4250 | 0.6299 |
| 10:55 ET | 487 | 0.6202 |
| 10:57 ET | 4100 | 0.6299 |
| 11:00 ET | 5000 | 0.6299 |
| 11:02 ET | 2000 | 0.62286 |
| 11:04 ET | 222 | 0.6299 |
| 11:08 ET | 222 | 0.6211 |
| 11:13 ET | 8031 | 0.63 |
| 11:15 ET | 8100 | 0.63 |
| 11:42 ET | 1600 | 0.625 |
| 11:58 ET | 12000 | 0.63 |
| 12:03 ET | 100 | 0.6254 |
| 12:16 ET | 300 | 0.6255 |
| 12:34 ET | 772 | 0.629999 |
| 12:39 ET | 438 | 0.629447 |
| 01:15 ET | 100 | 0.6255 |
| 01:17 ET | 1000 | 0.6256 |
| 01:21 ET | 7477 | 0.62 |
| 01:37 ET | 1100 | 0.6113 |
| 01:39 ET | 175 | 0.6114 |
| 01:46 ET | 350 | 0.6115 |
| 01:48 ET | 3500 | 0.62 |
| 01:50 ET | 2500 | 0.6199 |
| 02:00 ET | 2703 | 0.62 |
| 02:04 ET | 100 | 0.63 |
| 02:06 ET | 3000 | 0.63 |
| 02:22 ET | 2000 | 0.6299 |
| 02:26 ET | 3000 | 0.6201 |
| 02:42 ET | 315 | 0.6201 |
| 03:03 ET | 2650 | 0.63 |
| 03:14 ET | 3200 | 0.6299 |
| 03:34 ET | 500 | 0.627 |
| 03:38 ET | 16704 | 0.63 |
| 03:45 ET | 368 | 0.63 |
| 03:48 ET | 2000 | 0.63 |
| 03:54 ET | 53454 | 0.644 |
| 03:57 ET | 500 | 0.633 |
| 03:59 ET | 1191 | 0.6211 |
Sep 4, 2024
DJ BioLine RX Initiated at Buy by Jones Trading, from 12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
Aug 15, 2024
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Thursday Aug 15, 2024 by Dow Jones
7:00AM ET on Thursday Aug 15, 2024 by Dow JonesPress Release: BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Thursday Aug 15, 2024 by Dow Jones
7:00AM ET on Thursday Aug 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 54.9M | -0.8x | --- |
Kronos Bio Inc | 57.3M | -0.5x | --- |
LAVA Therapeutics NV | 45.2M | -1.9x | --- |
Atara Biotherapeutics Inc | 55.0M | -0.2x | --- |
Kezar Life Sciences Inc | 41.6M | -0.4x | --- |
Armata Pharmaceuticals Inc | 82.3M | -1.2x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.9M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
